From Biosimilars To A Flexible CDMO Model: Rezon Bio's Strategy For Growth

Transitioning from biosimilar development to a flexible manufacturing model requires deep scientific expertise, a robust risk-sharing mindset, and a thorough understanding of the entire product lifecycle. Successful contract manufacturing partnerships depend on more than sheer capacity alone; they require an ability to minimize complexity, anticipate potential bottlenecks early, and align technical execution with commercial realities. Organizations benefit significantly when service providers perform critical testing internally, such as advanced mass spectrometry and structural characterization, which ensures greater control over quality, timelines, and budgets. Furthermore, balancing technological innovation with operational robustness helps safeguard supply chains against unforeseen disruptions while maintaining strict regulatory compliance across global markets.

Explore the full article to learn how strategic flexibility and firsthand development experience drive long-term success for advanced biological therapies.